EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12 month price targets for EyePoint Pharmaceuticals' stock. Their EYPT share price forecasts range from $22.00 to $52.00. On average, they anticipate the company's stock price to reach $33.00 in the next year. This suggests a possible upside of 313.0% from the stock's current price.
View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts.

EyePoint Pharmaceuticals' stock was trading at $3.50 at the start of the year. Since then, EYPT stock has increased by 128.3% and is now trading at $7.99.
View the best growth stocks for 2023 here.

EyePoint Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 6,180,000 shares, an increase of 9.2% from the August 31st total of 5,660,000 shares. Based on an average daily trading volume, of 606,000 shares, the short-interest ratio is currently 10.2 days. Currently, 22.3% of the shares of the company are sold short.
View EyePoint Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our EYPT earnings forecast.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of $0.41 by $1.02. The firm earned $9.11 million during the quarter, compared to the consensus estimate of $79.03 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 92.58% and a negative net margin of 283.81%.

EyePoint Pharmaceuticals shares reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYPT stock can currently be purchased for approximately $7.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $279.49 million and generates $41.40 million in revenue each year. The company earns $-102,250,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

The company employs 144 workers across the globe.

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.